CRY - CryoLife, Inc.

NYSE - NYSE Delayed Price. Currency in USD

CryoLife, Inc.

1655 Roberts Boulevard NW
Kennesaw, GA 30144
United States

IndustryMedical Appliances & Equipment
Full Time Employees1,000

Key Executives

NameTitlePayExercisedYear Born
Mr. James Patrick MacKinChairman, Pres & CEO1.23MN/A1967
Mr. David Ashley LeeExec. VP, COO & CFO716k452.79k1965
Ms. Jean F. HollowaySr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.526.04k22.16k1957
Mr. John E. DavisSr. VP of Global Sales & Marketing519.16kN/A1965
Ms. Amy D. HortonVP & Chief Accounting OfficerN/AN/A1970
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries. The company also provides cardiac laser therapy products, which include laser consoles, related service and maintenance, and single-use, as well as fiber-optic hand-pieces for the treatment of coronary artery disease in patients with severe angina. In addition, it distributes E-vita OPEN PLUS, a hybrid stent graft systems for the surgical and endovascular treatment; E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; E-vita THORACIC 3G is a stent graft system for the endovascular treatment of thoracic aortic aneurysms; and E-tegra, an abdominal aortic aneurysms stent graft system for the endovascular treatment. Further, the company offers vascular preservation services; and synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures. The company serves physicians, hospitals, and other healthcare industries, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

Corporate Governance

CryoLife, Inc.’s ISS Governance QualityScore as of March 1, 2018 is 2. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 3; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.